Cluster analysis of genomic ETV6-RUNX1 (TEL-AML1) fusion sites in childhood acute lymphoblastic leukemia. 2009

H von Goessel, and U Jacobs, and S Semper, and M Krumbholz, and T Langer, and T Keller, and A Schrauder, and V H J van der Velden, and J J M van Dongen, and J Harbott, and E R Panzer-Grümayer, and M Schrappe, and W Rascher, and M Metzler
Department of Pediatrics, University of Erlangen, Erlangen, Germany.

Fusion between ETV6 and RUNX1 defines the largest genetic subgroup in childhood ALL. The genomic fusion site, unique to individual patients and specific for the malignant clone, represents an ideal molecular marker for quantification of minimal residual disease. Sequencing of DNA breakpoints has been difficult due to the extended size of the respective breakpoint cluster regions. We therefore evaluated a specially designed multiplex long-range PCR assay in 65 diagnostic bone marrow samples for its suitability in routine use. Resulting fusion sites and breakpoints derived from previous studies were subject to cluster analysis to identify potential sequence motifs involved in translocation initiation.

UI MeSH Term Description Entries
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015514 Oncogene Proteins, Fusion The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin. Chimeric Oncogene Proteins,Chimeric Proteins, Oncogene,Fusion Proteins, Oncogene,Oncogene Fusion Proteins,Oncogene Proteins, Chimeric,Fusion Oncogene Proteins,Oncogene Chimeric Proteins,Proteins, Chimeric Oncogene,Proteins, Fusion Oncogene,Proteins, Oncogene Chimeric,Proteins, Oncogene Fusion
D016133 Polymerase Chain Reaction In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. Anchored PCR,Inverse PCR,Nested PCR,PCR,Anchored Polymerase Chain Reaction,Inverse Polymerase Chain Reaction,Nested Polymerase Chain Reaction,PCR, Anchored,PCR, Inverse,PCR, Nested,Polymerase Chain Reactions,Reaction, Polymerase Chain,Reactions, Polymerase Chain
D050676 Core Binding Factor Alpha 2 Subunit A transcription factor that dimerizes with the cofactor CORE BINDING FACTOR BETA SUBUNIT to form core binding factor. It contains a highly conserved DNA-binding domain known as the runt domain. Runx1 is frequently mutated in human LEUKEMIAS. AML1A Protein,AML1B Protein,AML1C Protein,AML1D Protein,Acute Myeloid Leukemia 1 Protein,Acute Myeloid Leukemia 1A Protein,Acute Myeloid Leukemia 1B Protein,Acute Myeloid Leukemia 1C Protein,Acute Myeloid Leukemia 1D Protein,Core-Binding Factor Alpha 2 Protein,Pebp2a2 Protein,Runt-Related Transcription Factor 1,Runx1 Protein,Core Binding Factor Alpha 2 Protein,Runt Related Transcription Factor 1

Related Publications

H von Goessel, and U Jacobs, and S Semper, and M Krumbholz, and T Langer, and T Keller, and A Schrauder, and V H J van der Velden, and J J M van Dongen, and J Harbott, and E R Panzer-Grümayer, and M Schrappe, and W Rascher, and M Metzler
February 2004, Cancer genetics and cytogenetics,
H von Goessel, and U Jacobs, and S Semper, and M Krumbholz, and T Langer, and T Keller, and A Schrauder, and V H J van der Velden, and J J M van Dongen, and J Harbott, and E R Panzer-Grümayer, and M Schrappe, and W Rascher, and M Metzler
July 1999, Blood,
H von Goessel, and U Jacobs, and S Semper, and M Krumbholz, and T Langer, and T Keller, and A Schrauder, and V H J van der Velden, and J J M van Dongen, and J Harbott, and E R Panzer-Grümayer, and M Schrappe, and W Rascher, and M Metzler
January 2017, PloS one,
H von Goessel, and U Jacobs, and S Semper, and M Krumbholz, and T Langer, and T Keller, and A Schrauder, and V H J van der Velden, and J J M van Dongen, and J Harbott, and E R Panzer-Grümayer, and M Schrappe, and W Rascher, and M Metzler
January 2011, Blood,
H von Goessel, and U Jacobs, and S Semper, and M Krumbholz, and T Langer, and T Keller, and A Schrauder, and V H J van der Velden, and J J M van Dongen, and J Harbott, and E R Panzer-Grümayer, and M Schrappe, and W Rascher, and M Metzler
June 2008, The Kaohsiung journal of medical sciences,
H von Goessel, and U Jacobs, and S Semper, and M Krumbholz, and T Langer, and T Keller, and A Schrauder, and V H J van der Velden, and J J M van Dongen, and J Harbott, and E R Panzer-Grümayer, and M Schrappe, and W Rascher, and M Metzler
February 1999, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
H von Goessel, and U Jacobs, and S Semper, and M Krumbholz, and T Langer, and T Keller, and A Schrauder, and V H J van der Velden, and J J M van Dongen, and J Harbott, and E R Panzer-Grümayer, and M Schrappe, and W Rascher, and M Metzler
February 2003, Leukemia,
H von Goessel, and U Jacobs, and S Semper, and M Krumbholz, and T Langer, and T Keller, and A Schrauder, and V H J van der Velden, and J J M van Dongen, and J Harbott, and E R Panzer-Grümayer, and M Schrappe, and W Rascher, and M Metzler
April 2002, Leukemia,
H von Goessel, and U Jacobs, and S Semper, and M Krumbholz, and T Langer, and T Keller, and A Schrauder, and V H J van der Velden, and J J M van Dongen, and J Harbott, and E R Panzer-Grümayer, and M Schrappe, and W Rascher, and M Metzler
August 2007, Pediatric blood & cancer,
H von Goessel, and U Jacobs, and S Semper, and M Krumbholz, and T Langer, and T Keller, and A Schrauder, and V H J van der Velden, and J J M van Dongen, and J Harbott, and E R Panzer-Grümayer, and M Schrappe, and W Rascher, and M Metzler
January 1998, Journal of pediatric hematology/oncology,
Copied contents to your clipboard!